Korean Journal of Pediatrics 2006;49(6):581-588.
Published online June 15, 2006.
Update in asthma management
Hae Ran Lee
Department of Pediatrics, Medical College, Hallym University, Seoul, Korea
천식치료의 최신지견
이혜란
한림대학교 의과대학 소아과학교실
Correspondence: 
Hae Ran Lee, Email: drran@hallym.or.kr
Abstract
Asthma is a chronic inflammation of the airway associated with increased bronchial hyperresponsiveness that leads to recurrent episodes of cough, wheezing, breathless, chest tightness. According the recent studies, repeated airway inflammation leads to structural changes so called ‘airway remodeling’ and associated with decreased pulmonary function. Airway remodeling begins form the early stage of asthma and the early diagnosis and management is very important to prevent airway remodeling. Medication for asthma can be classified into acute symptom reliever and chronic controller. Short acting beta2 agonist is a well-known reliever that reduced asthma symptoms within minutes. Controllers should be taken daily as a long-term basis to control airway inflammation. Inhaled corticosteroid(ICS) is the most effective controller in current use. However, in some patients ICS monotherapy is not sufficient to control asthma. In those cases, other medications such as long acting beta2 agonist, leukotriene modifier or sustained-release theophylline should be added to ICS, which called Add-on-Therapy. Combination inhaler devices are easy to use. Oral leukotriene modifier has a good compliance especially in children. Finally, as asthma is a chronic disease, the development of on-going partnership among health care professionals, the patients, and the patients' family is necessary for the effective management of asthma.
Key Words: Asthma , Management , Guideline


METRICS Graph View
  • 2,614 View
  • 37 Download


Close layer
prev next